Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)

Di Bacco Alessandra; Bahlis Nizar J.; Munshi Nikhil C.; Avet-Loiseau Herve; Masszi Tamas; Viterbo Luisa; Pour Ludek; Ganly Peter; Cavo Michele; Langer Christian; Kumar Shaji; Rajkumar S. Vincent; Berg Deborah; Lin Jianchang; Li Bin; Badola Sunita; Shen Lei; Zhang Jacob; Wang Ling; Esseltine Dixie-Lee; Luptakova Katarina; de Velde Helgi van; Richardson Paul G.; Moreau Philippe

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)

【24h】

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)

机译：较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松（IRd）无进展生存期（PFS）相对于安慰剂-Rd的关联：电气石-MM1期3期研究在复发/难治性多发性骨髓瘤（RRMM）中的生物标志物分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共7页
作者
Di Bacco Alessandra; Bahlis Nizar J.; Munshi Nikhil C.; Avet-Loiseau Herve; Masszi Tamas; Viterbo Luisa; Pour Ludek; Ganly Peter; Cavo Michele; Langer Christian; Kumar Shaji; Rajkumar S. Vincent; Berg Deborah; Lin Jianchang; Li Bin; Badola Sunita; Shen Lei; Zhang Jacob; Wang Ling; Esseltine Dixie-Lee; Luptakova Katarina; de Velde Helgi van; Richardson Paul G.; Moreau Philippe;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM) [J] . Di Bacco Alessandra, Bahlis Nizar J., Munshi Nikhil C., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松（IRd）无进展生存期（PFS）相对于安慰剂-Rd的关联：电气石-MM1期3期研究在复发/难治性多发性骨髓瘤（RRMM）中的生物标志物分析
2. Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM) [J] . Di Bacco Alessandra, Bahlis Nizar J., Munshi Nikhil C., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松（IRd）无进展生存期（PFS）相对于安慰剂-Rd的关联：电气石-MM1期3期研究在复发/难治性多发性骨髓瘤（RRMM）中的生物标志物分析
3. Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies [J] . Fu Weijun, Lu Jin, Jin Jie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：口腔Ixazomib的整体存活（OS）益处与Lenalalomide和Dexamethasone（IRD）与亚洲患者（PTS）组合的亚洲患者（PTS）的益处（PTS）组合，具有复发和/或难治性多骨髓瘤（RRMM）：汇总 - 从陀螺俱乐部分析 - MM1和中国延续研究
4. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
5. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 [O] . María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, 2017

机译：在TOURMALINE-MM1复发/难治性多发性骨髓瘤患者中既往治疗对口服艾达唑仑-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的疗效和安全性的影响
6. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 [O] . Mateos, María-Victoria, Masszi, Tamas, Grzasko, Norbert, 2017

机译：先前疗法对口服伊沙唑嘧啶 - 来那度胺 - 地塞米松与安慰剂 - 来那度胺 - 地塞米松治疗TOURmaLINE-mm1复发/难治性多发性骨髓瘤疗效和安全性的影响

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)

著录项

相似文献

相关主题

期刊订阅